Skip to main content
D

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,124 across all filing types
Latest filing 2019-08-28 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Appendix 4G and Corporate Governance Statement 17 pages 387.3KB
Regulatory Filings
2019-08-28 English
Annual Report to shareholders 72 pages 3.6MB
Regulatory Filings
2019-08-28 English
Appendix 3B 13 pages 424.2KB
Regulatory Filings
2019-08-08 English
Dimerix to Present at Bioshares Biotech Summit 2019 19 pages 1.0MB
Regulatory Filings
2019-07-24 English
Quarterly Commentary & Appendix 4C 6 pages 355.6KB
Regulatory Filings
2019-07-15 English
First DMX-200 Patents To Grant In Europe And Canada 2 pages 193.2KB
Regulatory Filings
2019-07-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.